---
document_datetime: 2025-12-02 05:15:17
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/invega.html
document_name: invega.html
version: success
processing_time: 0.2924143
conversion_datetime: 2025-12-24 01:09:24.375118
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Invega

[RSS](/en/individual-human-medicine.xml/66306)

##### Authorised

This medicine is authorised for use in the European Union

paliperidone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Invega](#news-on)
- [More information on Invega](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Invega. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Invega.

For practical information about using Invega, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Invega and what is it used for?

Invega is an antipsychotic medicine used in adults and adolescents from 15 years of age to treat schizophrenia, a mental illness with symptoms such as disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).

Invega is also used to treat adults with schizoaffective disorder. This is a condition in which the patient has episodes of elevated mood (mania) or low mood (depression) in addition to symptoms of schizophrenia.

Invega contains the active substance paliperidone.

## How is Invega used?

Invega can only be obtained with a prescription. It is available as prolonged-release tablets (3, 6, 9 and 12 mg). 'Prolonged release' means that paliperidone is released slowly from the tablet over a few hours.

The recommended starting dose of Invega in adults is 6 mg once a day, taken in the morning; the starting dose in adolescents is 3 mg daily. Patients can take Invega either with food or between meals, but should not switch between taking it with food on one day and between meals on another. After assessing the symptoms, the doctor may adjust the dose to between 3 and 12 mg once a day in adults with schizophrenia and to between 6 and 12 mg once a day in patients with schizoaffective disorder. In adolescents with schizophrenia the maximum daily dose depends on the patient's body weight and should not be more than 6 mg in those who weigh less than 51 kg. For more information on the use of Invega, including the adjustment of doses in those with kidney disease and the elderly, see the summary of product characteristics (also part of the EPAR).

## How does Invega work?

The active substance in Invega, paliperidone, is known as an 'atypical' antipsychotic because it is different from the older antipsychotic medicines that have been available since the 1950s. Paliperidone is an active breakdown product (metabolite) of risperidone, another atypical antipsychotic medicine that has been used in the treatment of schizophrenia since the 1990s. In the brain, paliperidone attaches to several different receptors (targets) on nerve cells. This disrupts signals sent between brain cells by 'neurotransmitters', substances that nerve cells use to communicate with neighbouring cells. Paliperidone acts mainly by blocking the receptors for the neurotransmitters dopamine and 5?hydroxytryptamine (also called serotonin), which are involved in schizophrenia. By blocking these receptors, paliperidone helps to normalise the activity of the brain and reduce symptoms.

## What benefits of Invega have been shown in studies?

**Schizophrenia**

Three short-term studies innvolving 1,692 adults showed that Invega is more effective than placebo (a dummy treatment) and as effective as another antipsychotic medicine olanzapine at reducing symptoms of schizophrenia (as measured by a standard rating scale). In one of these studies, average symptom scores fell by between 17.9 and 23.3 points after 6 weeks in those taking Invega compared with a fall of 4.1 points with placebo. Symptom scores fell by 19.9 points in those taking olanzapine. Similar results were seen in the other two short-term studies, with higher doses of Invega being more effective than lower doses.

In an additional longer-term study involving 207 adults with schizophrenia who had initially been treated over 14 weeks, Invega was more effective than placebo in preventing new symptoms for up to 35 weeks.

Studies in adolescents have shown similar results with Invega to those seen in adults.

**Schizoaffective disorder**

Studies have shown that Invega can reduce symptoms scores and prevent symptoms in patients with schizoaffective disorder.

In one study, patients who were given Invega had a fall in their symptom score for mania of between 27.4 and 30.6 after 6 weeks compared with 21.7 in patients who were given placebo. In another study, the fall in symptom score for mania after 6 weeks was 20.0 in the Invega group and 10.8 in the placebo group. The two studies together involved a total of 614 patients.

In a third study of 334 previously treated patients, symptoms of depression came back in 15% (25 out of 164) of patients given paliperidone compared with 34% (57 out of 170) of patients given placebo.

## What are the risks associated with Invega?

The most frequent side effects with Invega in adults are headache, insomnia (difficulty sleeping), sleepiness, parkinsonism (effects similar to Parkinson's disease such as shaking, muscle stiffness and slow movement), dystonia (involuntary muscle contractions), tremor (shaking), dizziness, akathisia (restlessness), agitation, anxiety, depression, increased weight, nausea, vomiting, constipation, dyspepsia (heartburn), diarrhoea, dry mouth, tiredness, toothache, muscle and bone pain, back pain, asthenia (weakness), tachycardia (increased heart rate), high blood pressure, prolonged QT interval (an alteration of the electrical activity of the heart), upper respiratory tract infection (nose and throat infections) and cough. Side effects in adolescents are similar to those in adults, although some side effects may occur more frequently. For the full list of all side effects reported with Invega, see the package leaflet.

Invega must not be taken by people who are hypersensitive (allergic) to paliperidone or any of the other ingredients, or to risperidone.

## Why is Invega approved?

The European Medicines Agency decided that Invega's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Invega?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Invega have been included in the summary of product characteristics and the package leaflet.

## Other information about Invega

The European Commission granted a marketing authorisation valid throughout the European Union for Invega on 25 June 2007.

For more information about treatment with Invega, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Invega : EPAR - Summary for the public

English (EN) (80.9 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 19/09/2017

[View](/en/documents/overview/invega-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-681)

български (BG) (107.17 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/bg/documents/overview/invega-epar-summary-public_bg.pdf)

español (ES) (79.7 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/es/documents/overview/invega-epar-summary-public_es.pdf)

čeština (CS) (106.41 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/cs/documents/overview/invega-epar-summary-public_cs.pdf)

dansk (DA) (78.45 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/da/documents/overview/invega-epar-summary-public_da.pdf)

Deutsch (DE) (81.07 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/de/documents/overview/invega-epar-summary-public_de.pdf)

eesti keel (ET) (78.96 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/et/documents/overview/invega-epar-summary-public_et.pdf)

ελληνικά (EL) (109.69 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/el/documents/overview/invega-epar-summary-public_el.pdf)

français (FR) (80.89 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/fr/documents/overview/invega-epar-summary-public_fr.pdf)

hrvatski (HR) (101.99 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/hr/documents/overview/invega-epar-summary-public_hr.pdf)

italiano (IT) (78.96 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/it/documents/overview/invega-epar-summary-public_it.pdf)

latviešu valoda (LV) (104.12 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/lv/documents/overview/invega-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (104.6 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/lt/documents/overview/invega-epar-summary-public_lt.pdf)

magyar (HU) (101.01 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/hu/documents/overview/invega-epar-summary-public_hu.pdf)

Malti (MT) (108.51 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/mt/documents/overview/invega-epar-summary-public_mt.pdf)

Nederlands (NL) (78.94 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/nl/documents/overview/invega-epar-summary-public_nl.pdf)

polski (PL) (106.7 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/pl/documents/overview/invega-epar-summary-public_pl.pdf)

português (PT) (79.82 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/pt/documents/overview/invega-epar-summary-public_pt.pdf)

română (RO) (103.35 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/ro/documents/overview/invega-epar-summary-public_ro.pdf)

slovenčina (SK) (105.97 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/sk/documents/overview/invega-epar-summary-public_sk.pdf)

slovenščina (SL) (100.05 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/sl/documents/overview/invega-epar-summary-public_sl.pdf)

Suomi (FI) (88.44 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/fi/documents/overview/invega-epar-summary-public_fi.pdf)

svenska (SV) (78.97 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

19/09/2017

[View](/sv/documents/overview/invega-epar-summary-public_sv.pdf)

Invega : EPAR - Risk-management-plan summary

English (EN) (88.97 KB - PDF)

**First published:** 13/08/2020

[View](/en/documents/rmp-summary/invega-epar-risk-management-plan-summary_en.pdf)

## Product information

Invega : EPAR - Product information

English (EN) (290.81 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 12/07/2024

[View](/en/documents/product-information/invega-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-984)

български (BG) (343.6 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/bg/documents/product-information/invega-epar-product-information_bg.pdf)

español (ES) (304.73 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/es/documents/product-information/invega-epar-product-information_es.pdf)

čeština (CS) (305.29 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/cs/documents/product-information/invega-epar-product-information_cs.pdf)

dansk (DA) (296.92 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/da/documents/product-information/invega-epar-product-information_da.pdf)

Deutsch (DE) (326.81 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/de/documents/product-information/invega-epar-product-information_de.pdf)

eesti keel (ET) (292.85 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/et/documents/product-information/invega-epar-product-information_et.pdf)

ελληνικά (EL) (327.9 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/el/documents/product-information/invega-epar-product-information_el.pdf)

français (FR) (318.05 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/fr/documents/product-information/invega-epar-product-information_fr.pdf)

hrvatski (HR) (288.98 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/hr/documents/product-information/invega-epar-product-information_hr.pdf)

íslenska (IS) (299.82 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/is/documents/product-information/invega-epar-product-information_is.pdf)

italiano (IT) (312.7 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/it/documents/product-information/invega-epar-product-information_it.pdf)

latviešu valoda (LV) (291.21 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/lv/documents/product-information/invega-epar-product-information_lv.pdf)

lietuvių kalba (LT) (312.14 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/lt/documents/product-information/invega-epar-product-information_lt.pdf)

magyar (HU) (311.97 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/hu/documents/product-information/invega-epar-product-information_hu.pdf)

Malti (MT) (348.83 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/mt/documents/product-information/invega-epar-product-information_mt.pdf)

Nederlands (NL) (318.52 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/nl/documents/product-information/invega-epar-product-information_nl.pdf)

norsk (NO) (284.17 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/no/documents/product-information/invega-epar-product-information_no.pdf)

polski (PL) (306.63 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/pl/documents/product-information/invega-epar-product-information_pl.pdf)

português (PT) (302.83 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/pt/documents/product-information/invega-epar-product-information_pt.pdf)

română (RO) (317.01 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/ro/documents/product-information/invega-epar-product-information_ro.pdf)

slovenčina (SK) (321.14 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sk/documents/product-information/invega-epar-product-information_sk.pdf)

slovenščina (SL) (287.57 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sl/documents/product-information/invega-epar-product-information_sl.pdf)

Suomi (FI) (297.8 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/fi/documents/product-information/invega-epar-product-information_fi.pdf)

svenska (SV) (276.79 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sv/documents/product-information/invega-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IA/0073 09/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Invega : EPAR - All Authorised presentations

English (EN) (56.96 KB - PDF)

**First published:** 04/03/2009

**Last updated:** 12/07/2024

[View](/en/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-972)

български (BG) (33.39 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/bg/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_bg.pdf)

español (ES) (31.57 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/es/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.78 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/cs/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.74 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/da/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (72.91 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/de/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (30.66 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/et/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (41.18 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/el/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_el.pdf)

français (FR) (55.07 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/fr/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.9 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/hr/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (55.77 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/is/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_is.pdf)

italiano (IT) (36.12 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/it/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.14 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/lv/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (30.95 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/lt/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.2 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/hu/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.18 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/mt/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.47 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/nl/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (56.25 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/no/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_no.pdf)

polski (PL) (64.83 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/pl/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_pl.pdf)

português (PT) (38.65 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/pt/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.13 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/ro/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.66 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sk/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.79 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sl/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.59 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/fi/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (54.92 KB - PDF)

**First published:**

04/03/2009

**Last updated:**

12/07/2024

[View](/sv/documents/all-authorised-presentations/invega-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Invega Active substance paliperidone International non-proprietary name (INN) or common name paliperidone Therapeutic area (MeSH)

- Schizophrenia
- Psychotic Disorders

Anatomical therapeutic chemical (ATC) code N05AX13

### Pharmacotherapeutic group

Psycholeptics

### Therapeutic indication

Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.

Invega is indicated for the treatment of schizoaffective disorder in adults.

## Authorisation details

EMA product number EMEA/H/C/000746 Marketing authorisation holder

Janssen-Cilag International NV

Turnhoutseweg, 30

Marketing authorisation issued 24/06/2007 Revision 19

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Invega : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (205.51 KB - PDF)

**First published:** 21/12/2009

**Last updated:** 12/07/2024

[View](/en/documents/procedural-steps-after/invega-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Invega-H-C-746-II-0043 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/213560/2015

English (EN) (3.98 MB - PDF)

**First published:** 16/07/2015

**Last updated:** 16/07/2015

[View](/en/documents/variation-report/invega-h-c-746-ii-0043-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Invega

Adopted

Reference Number: EMA/CHMP/245423/2015

English (EN) (66.96 KB - PDF)

**First published:** 24/04/2015

**Last updated:** 24/04/2015

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf-0)

Invega : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/339030/2014

English (EN) (68.88 KB - PDF)

**First published:** 12/06/2014

**Last updated:** 12/06/2014

[View](/en/documents/pip-compliance/invega-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Invega-H-C-746-II-0037 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/339041/2014

English (EN) (4 MB - PDF)

**First published:** 12/06/2014

**Last updated:** 12/06/2014

[View](/en/documents/variation-report/invega-h-c-746-ii-0037-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Invega

Adopted

Reference Number: EMA/243851/2014

English (EN) (67.26 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 25/04/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf-1)

Invega-H-C-746-A45-0010 : EPAR - Assessment Report

Adopted

Reference Number: EMA/579559/2012

English (EN) (290.56 KB - PDF)

**First published:** 19/09/2012

**Last updated:** 19/09/2012

[View](/en/documents/variation-report/invega-h-c-746-a45-0010-epar-assessment-report_en.pdf)

Invega-H-C-746-II-0023: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/179857/2011

English (EN) (2.52 MB - PDF)

**First published:** 27/05/2011

**Last updated:** 27/05/2011

[View](/en/documents/variation-report/invega-h-c-746-ii-0023-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Invega

Adopted

Reference Number: EMA/CHMP/444944/2010

English (EN) (56.65 KB - PDF)

**First published:** 01/10/2010

**Last updated:** 01/10/2010

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-invega_en.pdf)

## Initial marketing authorisation documents

Invega : EPAR - Scientific Discussion

English (EN) (1.13 MB - PDF)

**First published:** 16/07/2007

**Last updated:** 16/07/2007

[View](/en/documents/scientific-discussion/invega-epar-scientific-discussion_en.pdf)

Invega : EPAR - Procedural steps taken before authorisation

English (EN) (21.71 KB - PDF)

**First published:** 10/07/2007

**Last updated:** 10/07/2007

[View](/en/documents/procedural-steps/invega-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Invega

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 April 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-april-2015) 24/04/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

[Janssen-Cilag International N.V. withdraws its application for an extension of indication for Invega (paliperidone)](/en/news/janssen-cilag-international-nv-withdraws-its-application-extension-indication-invega-paliperidone) 17/12/2008

#### More information on Invega

- [Invega - withdrawal of application for variation to marketing authorisation](/en/medicines/human/variation/invega)
- [EMEA-000014-PIP01-07-M06 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000014-pip01-07-m06)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 12/07/2024

## Share this page

[Back to top](#main-content)